Haemonetics Corporation (HAE) Dividend History

Company News

• Global Blood Bank Market to Register Immense Growth at a CAGR of ~7% by 2032 | DelveInsight

  The global blood bank market is expected to grow significantly from 2025 to 2032, driven by the rising incidence of blood disorders, chronic illnesses, and accidents, as well as advancements in blood bank technologies and increased awareness about blood donation.

  GlobeNewswire Inc.

  Featured Companies: ABT BIO BIO.B CAH TMO
• [Latest] Global Apheresis Equipment Market Size/Share Worth USD 13,169.1 Million by 2033 at a 12.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

  The global apheresis equipment market is expected to grow from $4.17 billion in 2023 to $13.17 billion by 2033, at a CAGR of 12.2%. Key drivers include the increasing prevalence of chronic diseases, technological advancements, and growing demand for blood components.

  GlobeNewswire Inc.

  Featured Companies: BAX TMO
• Blood Recovery Machine Market is expected to reach revenue of USD 4,277.4 Mn by 2033, at 5.9% CAGR: Dimension Market Research.

  The global blood recovery machine market is expected to grow at a CAGR of 5.9% from 2024 to 2033, driven by advancements in medical technologies, increased awareness of autologous blood transfusion benefits, and rising demand for surgical procedures.

  GlobeNewswire Inc.

  Featured Companies: LIVN MDT
• Is Phibro (PAHC) Stock Worth Retaining in Your Portfolio Now?

  Phibro Animal Health Corporation's robust sales of vaccines and medicated feed additives (MFAs) are driving growth in its Animal Health business. The company's focus on advancing nutritional specialties and vaccine technologies, along with a new vaccine production unit, instills optimism. However, adverse macroeconomic impacts and growing competition from generic alternatives are concerns.

  Zacks Investment Research

  Featured Companies: AVNS PAHC TFX
• Thermo Fisher (TMO) Beats on Q2 Earnings, Raises 2024 EPS View - Zacks Investment Research

  Thermo Fisher Scientific reported better-than-expected Q2 2024 results, with adjusted EPS of $5.37 and revenue of $10.54 billion. The company saw margin expansion but a decline in both reported and organic revenues, particularly in the Life Sciences Solutions and Laboratory Products and Biopharma Services segments.

  Zacks Investment Research

  Featured Companies: GMED PODD TMO